Perspectives in adjuvant chemotherapy in NSCLC

Expert Review of Respiratory Medicine

Volumn 1, Issue 1, 2007, Pages 99-110

  Selvaggi, Giovanni ^a   Scagliotti, Giorgio Vittorio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

adjuvant chemotherapy; cisplatin; molecular targeted therapy; non small cell lung cancer; pharmacogenomics; surgery

Indexed keywords

EID: 84868105409     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.1.1.99     Document Type: Article

References (93)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J. Clin. 57, 43–66 (2007).
2. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics 2002. CA Cancer J. Clin. 55, 74–108 (2005).
3. Mountain CF. Revisions in the international system for staging lung cancer. Chest 111, 1710–1717 (1997).
4. Nesbitt JC, Putnam JB Jr, Walsh GL et al. Survival in early stage non-small cell lung cancer. Ann. Thorac. Surg. 60, 466–472 (1995).
5. Roth J, Atkinson E, Fossella F et al. Long-term follow up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage III A non-small-cell lung cancer. Lung Cancer 21, 1–6 (1998).
6. Rosell R, Gomez-Codina J, Camps C et al. Pre-resectional chemotherapy in stage III A non-small cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 26, 7–14 (1999).
7. Depierre A, Milleron B, Moro-Sibilot D et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and III A NSCLC. J. Clin. Oncol. 20, 247–253 (2002).
8. Pisters K, Vallieres E, Bunn P et al. S9900: a Phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results. J. Clin. Oncol. 23 (16S), 7012 (2005).
9. Burdett S, Stewart L, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J. Thoracic Oncol. 1, 611–621 (2006).
10. Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. PORT Meta-analysis Trialists Group. Lancet 352, 257–263 (1998).
11. Lally BE, Zelterman D, Colasanto JM et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the Surveillance, Epidemiology, and End Results database. J. Clin. Oncol. 24, 2998–3006 (2006).
12. Okawara G, Ung YC, Markman BR et al. Postoperative radiotherapy in stage II or III A completely resected non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 44, 1–11 (2004).
13. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J. 311, 899–909 (1995).
14. Hotta K, Matsuo K, Ueoka H et al. Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J. Clin. Oncol. 22, 3860–3867 (2004).
15. Keller SM, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIA non-small cell lung cancer. N. Engl. J. Med. 343, 1217–1222 (2000).
16. Schiller JH, Adak S, Feins RH et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized clinical trial of postoperative adjuvant therapy. J. Clin. Oncol. 19, 448–457 (2001).
17. Scagliotti GV, Fossati R, Torri V et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II or III A non-small cell lung cancer. J. Natl Cancer Inst. 95, 1453–1461 (2003).
18. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N. Engl. J. Med. 350, 351–360 (2004).
19. Waller D, Peake MD, Stephens RJ et al. Chemotherapy for patients with non-small cell lung cancer. The surgical setting of the Big Lung Trial. Eur. J. Cardio. Thorac. Surg. 26, 173–182 (2004).
20. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352, 2589–2597 (2005)
21. Douillard JY, Rosell R, Delena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-III A non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 7 (9), 719–727(2006).
22. Strauss GM, Herndon J, Maddaus MA et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J. Clin. Oncol. 22 (14S), 7019 (2004).
23. Strauss GM, Herndon J, Maddaus MA et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) Protocol 9633. J. Clin. Oncol. 24 (18S), 7007 (2006).
24. Kato H, Ichinose Y, Ohta M et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med. 350, 1713–1721 (2004).
25. Hamada C, Tanaka F, Ohta M et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur–uracil in non-small-cell lung cancer. J. Clin. Oncol. 23 (22), 4999–5006 (2005).
26. Sedrakyan A, van Der Meulen J, O’Byrne K et al. Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J. Thorac. Cardiovasc. Surg. 128, 414–419 (2004).
27. Pignon JP, Tribodet H, Scagliotti GV et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4584 patients. J. Clin. Oncol. 24 (18S), 7008 (2006).
28. Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur. J. Cancer 33, 2313–2314 (1997).
29. Pepe C, Hasan B, Winton T et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J. Clin. Oncol. 25, 1553–1561 (2007).
30. Cerny T, Barnes DM, Hasleton P et al. Expression of epidermal growth factor receptor (EGF-R) in human lung tumors. Br. J. Cancer 54, 265–269 (1986).
31. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787–2799 (2003).
32. Tateishi M, Ishida T, Mitsudomi T et al. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res. 50, 7077–7080 (1990).
33. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 61 (2), 140–145 (2006).
34. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149–2158 (2003)
35. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21, 2237–2246 (2003).
36. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicenter study (Iressa survival evaluation in lung cancer). Lancet 366, 1527–1537 (2005).
37. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 1. J. Clin. Oncol. 22, 777–784 (2004).
38. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: A Phase III trial–INTACT 2. J. Clin. Oncol. 22, 785–794 (2004).
39. Shepherd FA, Pereira PR, Ciulenau T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123–132 (2005).
40. Gatzemeier U, Pluzanska A, Szczesna A et al. Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 22 (14S), 7010 (2004)
41. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5892–5899 (2005).
42. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
43. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
44. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306–13311 (2004).
45. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97, 643–655 (2005).
46. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21, 3798–3807 (2003).
47. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542–2550 (2006).
48. The FDA approves drugs for colorectal cancer, lung cancer. FDA Consum. 41 (1), 5 (2007).
49. Dohadwala M, Batra RK, Luo J et al. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J. Biol. Chem. 277, 50828–50833 (2002).
50. Krysan K, Merchant FH, Zhu L et al. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J. 18, 206–208 (2004).
51. Hida T, Kozaki K, Muramatsu H et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 6, 2006–2011 (2000).
52. Edelman MJ, Watson DM, Wang X et al. Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203. J. Clin. Oncol. 24 (18S), 7025 (2006).
53. Lilenbaum R, Socinski MA, Altorki NK et al. Randomized Phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J. Clin. Oncol. 24, 4825–4832 (2006).
54. Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J. Thorac. Oncol. 2 (4), 299–305 (2007).
55. Su D, Ma S, Liu P et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 56 (2), 281–288 (2007).
56. Lord RVN, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin. Cancer Res. 8, 2286–2291 (2002).
57. Suk R, Gurubhagavatula S, Park S et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin. Cancer Res. 11, 1534–1538 (2005).
58. Bepler G, Gautam A, McIntyre LM et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J. Clin. Oncol. 20, 1353–1360 (2002).
59. Bepler G, Sharma S, Cantor A et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J. Clin. Oncol. 22, 1878–1885 (2004).
60. Bepler G, Kusmartseva I, Sharma S et al. RRM1-modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 24, 4731–4737 (2006).
61. Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 17, 1818–1825 (2006).
62. Cobo M, Isla D, Sanchez J et al. ERCC1 mRNA-based randomized Phase III trial of docetaxel doublets with cisplatin or gemcitabine in stage IV non-small-cell lung cancer patients. Lung Cancer 49 (Suppl. 2), S32 (2005).
63. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355, 983–991 (2006).
64. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 8, 1323–1327 (2002).
65. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 356 (8), 800–808 (2007)
66. Santi DV, Danenberg PV. Folates in pyrimidine nucleotide biosynthesis. In: Folates and pterins (Volume 1). Blakley RL, Benkovic SJ (Eds). John Wiley & Sons, Inc. NY, USA 231–345 (1984).
67. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55, 1407–1412 (1995).
68. Edler D, Kressner U, Ragnhammar P et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin. Cancer Res. 6, 488–492 (2000).
69. Pestalozzi BC, Peterson HF, Gelber RD et al. Prognostic importance of thymidylate synthase expression in early breast cancer. J. Clin. Oncol. 15, 1923–1931 (1997).
70. Nakagawa T, Tanaka F, Otake Y et al. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 35, 165–170 (2002).
71. Higashiyama M, Kodama K, Yokouchi H et al. Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil. Lung Cancer 34, 407–416 (2001).
72. Dumontet C, Sikic BI. Mechanisms of action and resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J. Clin. Oncol. 17, 1061–1070 (1999).
73. Kamath K, Wilson L, Cabral F, Jordan MA. β III-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J. Biol. Chem. 280, 12902–12907 (2005).
74. Seve P, Isaac S, Tredan O et al. Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin. Cancer Res. 11, 5481–5486 (2005).
75. Rosell R, Scagliotti G, Danenberg KD et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22, 354835–354853 (2003).
76. Seve P, Mackey J, Isaac S et al. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol. Cancer Ther. 4 (12), 2001–2007 (2005).
77. Seve P, Lai R, Ding K et al. Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR. Clin. Cancer Res. 13 (3), 994–999 (2007)
78. Lih CJ, Wei W, Cohen SN. Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev. 20 (15), 2082–2095 (2006).
79. Quinn JE, Kennedy RD, Mullan PB et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63, 6221–6228 (2003).
80. Taron M, Rosell R, Felip E et al. BRCA mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet. 13, 2443–2449 (2004).
81. Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin. Cancer Res. 10, 1318–1325 (2004).
82. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N. Engl. J. Med. 352, 2589–2597 (2005).
83. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900–5909 (2005).
84. Stabile LP, Lyker J, Gubish CT et al. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 65, 1459–1470 (2005).
85. Ishibashi H, Suzuki T, Suzuki S et al. Progesterone receptor in non-small cell lung cancer: a potent prognostic factor and possible target for endocrine therapy. Cancer Res. 65, 6450–6458 (2005).
86. Jones DR, Daniel TM, Denlinger CE, Rundall BK, Smolkin ME, Wick MR. Stage IB non-small cell lung cancers: are they all the same? Ann. Thorac. Surg. 81 (6), 1958–1962 (2006).
87. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J. Clin. Oncol. 25 (5), 561–570 (2007).
88. Toh CK, Gao F, Lim WT et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J. Clin. Oncol. 24 (15), 2245–2251 (2006).
89. Potti A, Mukherjee S, Petersen R et al. A genomic strategy to refine prognosis in early-stage non–small-cell lung cancer. N. Engl. J. Med. 355, 570–580 (2006).
90. Su D, Ma S, Liu P et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 56 (2), 281–288 (2007).
91. Ceppi P, Volante M, Saviozzi S et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107 (7), 1589–1596 (2006).
92. Tsuchiya T, Akamine S, Muraoka M et al. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer 56 (3), 341–348 (2007).
93. National Cancer Institute www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=475774&version=HealthProfessional&protocolsearchid=2927573